Fixing anything requires tools like screwdrivers, hammers and now researchers have developed a tool capable of “fixing” blood vessel cells. 

Women who have had tonsillectomies or appendectomies appear to be more likely to get pregnant and get pregnant earlier, according to a study in the journal Fertility and Sterility. The effect is even more pronounced when women have had both procedures. 

FORT LAUDERDALE, Fla., Aug. 02, 2016 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OmniComm) (OTCQX:OMCM), a global leading provider of clinical data management technology, today announced that one of the top 5 medical research universities in the US, selected OmniComm TrialMaster® EDC and related services to conduct a series of clinical studies over a five year period. 

Some 77 million American baby boomers are currently in or near their the golden years, forcing the healthcare industry to accomodate their needs. As this population increasingly visits hospitals and doctors, the entire industry needs to change to handle the influx of patients.

Bookworms everywhere can attest how a good read can improve quality of life. But according to a new study published in the journal Social Science and Medicine, reading books could also help improve the length of a person’s life by up to two years, especially in elderly people. 

REDWOOD CITY, Calif., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Biotricity, Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company dedicated to delivering innovative, biometric remote monitoring solutions, has selected AT&T, Inc. as its preferred network partner for providing connectivity to the company’s medical devices.

Taking a patient's temperature can be a time-consuming duty for both patient and caregiver, but a new app and wearable patch aim to simplify the process.

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced that the first patient has been enrolled in a Phase 1/2 clinical trial assessing the safety and efficacy of CB-839.